Cancer

Mouse studies suggest STING agonists could help treat head and neck cancer. In a mouse model of head and neck cancer, a STING agonist tool compound eliminated tumors in five of 10 treated mice, and decreased tumor growth and increased survival in the other five mice compared with vehicle. In a mouse model of head and neck cancer relapse, the compound prevented tumor formation in five of five treated mice, and the compound plus an anti-PD-L1 antibody decreased tumor growth compared with either agent alone. Next steps include testing the combination of the STING agonist and radiotherapy in a model of head and neck cancer...